Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Research Article

Standardised ido-BR1 Cucumber Extract Improved Parameters Linked to Moderate Osteoarthritis in a Placebo-controlled Study

Author(s): Robert James Nash*, Amelie Mafongang, Harinder Singh, Madeleine Singwe-Ngandeu, Yana Boycheva Penkova, Taranjeet Kaur and Junai Akbar

Volume 19, Issue 3, 2023

Published on: 08 March, 2023

Page: [345 - 351] Pages: 7

DOI: 10.2174/1573397119666230206105703

Price: $65

Abstract

Background: According to the World Health Organization, osteoarthritis (OA) is one of the 10 most disabling diseases in developed countries, with worldwide estimates of 9.6% prevalence in men and 18.0% in women over 60 years old. Its management is not well established and involves the use of high doses of painkillers coupled with anti-inflammatory agents.

Objective: In the search for alternatives to manage the disease, previous studies have shown superior properties of Q-ActinTM in managing OA-related pain compared with standard treatments. Qactin is a cucumber extract with the anti-inflammatory iminosugar idoBR1 standardised to over 1%. This study investigated the effects of different doses (20 mg, 100 mg) of Q-Actin in a longitudinal placebo-controlled experiment.

Methods: There were 101 patients with knee OA enrolled for the 180-day study, with 91 patients completing it. Patients were grouped into a placebo group (PLBO), as well as a 20mg dose (Q-Actin 1) and 100 mg dose (Q-Actin 2) groups. The PLBO group received cellulose in capsules identical to the Q-Actin capsules.

Results: There was a significant improvement in the pain-related parameters over time that was dose-dependent.

Conclusion: This study clearly demonstrated the effectiveness of Q-Actin compared to placebo in the management of pain related to moderate osteoarthritis.

Keywords: Q-ActinTM, cucumber, osteoarthritis, Cucumis sativus, iminosugar, idoBR1.

Graphical Abstract
[1]
WHO.Musculoskeletal condition. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions
[2]
Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26(3): 355-69.
[http://dx.doi.org/10.1016/j.cger.2010.03.001] [PMID: 20699159]
[3]
Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014; 28(1): 5-15.
[http://dx.doi.org/10.1016/j.berh.2014.01.004] [PMID: 24792942]
[4]
Sharma L. Osteoarthritis year in review 2015: Clinical. Osteoarthritis Cartilage 2016; 24(1): 36-48.
[http://dx.doi.org/10.1016/j.joca.2015.07.026] [PMID: 26707991]
[5]
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15(12): 1833-40.
[PMID: 3068365]
[6]
Hayes MH, Patterson DG. Experimental development of the graphic rating method. Psychol Bull 1921; 18: 98-9.
[7]
Liu Y, Zhang H, Liang N, et al. Prevalence and associated factors of knee osteoarthritis in a rural Chinese adult population: An epidemiological survey. BMC Public Health 2015; 16(1): 94.
[http://dx.doi.org/10.1186/s12889-016-2782-x] [PMID: 26830813]
[8]
McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: A critical review. Psychol Med 1988; 18(4): 1007-19.
[http://dx.doi.org/10.1017/S0033291700009934] [PMID: 3078045]
[9]
Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997; 24(4): 779-81.
[PMID: 9101517]
[10]
Oben J, Enonchong E, Kothari S, Chambliss W, Garrison R, Dolnick D. Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: A pilot, double-blind, placebo-controlled study. Nutr J 2009; 8(1): 38.
[http://dx.doi.org/10.1186/1475-2891-8-38] [PMID: 19682376]
[11]
Bhatia D, Bejarano T, Novo M. Current interventions in the management of knee osteoarthritis. J Pharm Bioallied Sci 2013; 5(1): 30-8.
[http://dx.doi.org/10.4103/0975-7406.106561] [PMID: 23559821]
[12]
Mohd Yunus MH, Shuid AN, Busra MF, Chua KH, Abdul Ghafar N, Abd Rani R. The effect of Stichopus chloronotus aqueous extract on human osteoarthritis articular chondrocytes in three-dimensional collagen Type I hydrogel in vitro. Sains Malays 2019; 48(8): 1671-83.
[http://dx.doi.org/10.17576/jsm-2019-4808-13]
[13]
Nash RJ, Azantsa BKG, Sharp H, Shanmugham V. Effectiveness of Cucumis sativus extract versus glucosamine-chondroitin in the management of moderate osteoarthritis: A randomized controlled trial. Clin Interv Aging 2018; 13: 2119-26.
[http://dx.doi.org/10.2147/CIA.S173227] [PMID: 30498336]
[14]
Teslim OA, Daniel O, Nesto T, Adesola AO. Comparative effects of a single treatment session using glucosamine sulphate and methyl salicylate on pain and hamstring flexibility of patients with knee osteoarthritis. Am J Health Res 2014; 2(5): 40-4.
[http://dx.doi.org/10.11648/j.ajhr.s.2014020501.18]
[15]
Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162(18): 2113-23.
[http://dx.doi.org/10.1001/archinte.162.18.2113] [PMID: 12374520]
[16]
Zhang W, Robertson WB, Zhao J, Chen W, Xu J. emerging trend in the pharmacotherapy of osteoarthritis. Front Endocrinol (Lausanne) 2019; 10: 431.
[http://dx.doi.org/10.3389/fendo.2019.00431] [PMID: 31312184]
[17]
Siddiq MAB, Clegg D, Jansen TL, Rasker JJ. emerging and new treatment options for knee osteoarthritis. Curr Rheumatol Rev 2022; 18(1): 20-32.
[http://dx.doi.org/10.2174/1573397117666211116111738] [PMID: 34784876]
[18]
Newberry SJ, FitzGerald J. SooHoo, N.F.; Booth, M.; Marks, J.; Motala, A.; Apaydin, E.; Chen, C,; Raaen, L.; Shanman, R.; Shekelle, P.G. Treatment of Osteoarthritis of the Knee: An Update Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US), 2017, May Report No.: 17-EHC011-EF.
[PMID: 28825779]
[19]
Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69(8): 1459-64.
[http://dx.doi.org/10.1136/ard.2009.120469] [PMID: 20525840]
[20]
Kothari S, Saravana M, Muthusamy S, Mozingo A, Soni M. Safety assessment of a standardized cucumber extract (Q-Actin™): Oral repeat-dose toxicity and mutagenicity studies. Toxicol Rep 2018; 5: 1078-86.
[http://dx.doi.org/10.1016/j.toxrep.2018.10.014] [PMID: 30425929]
[21]
Nash RJ, Bartholomew B, Penkova YB, et al. Iminosugar idoBR1 isolated from cucumber Cucumis sativus reduces inflammatory activity. ACS Omega 2020; 5(26): 16263-71.
[http://dx.doi.org/10.1021/acsomega.0c02092] [PMID: 32656449]
[22]
Olajide OA, Iwuanyanwu VU, Banjo OW, et al. A; Iwuanyanwu, V.U.; Banjo, O.W.; Kato, A.; Penkova, Y.B.; Fleet, G.W.J.; Nash, R.J. Iminosugar amino acid idoBR1 reduces inflammatory responses in microglia. Molecules 2022; 27(10): 3342.
[http://dx.doi.org/10.3390/molecules27103342] [PMID: 35630818]
[23]
Zhang FJ, Luo W, Gao SG, et al. Expression of CD44 in articular cartilage is associated with disease severity in knee osteoarthritis. Mod Rheumatol 2013; 23(6): 1186-91.
[http://dx.doi.org/10.3109/s10165-012-0818-3] [PMID: 23283480]
[24]
Rigoglou S, Papavassiliou AG. The NF-κB signalling pathway in osteoarthritis. Int J Biochem Cell Biol 2013; 45(11): 2580-4.
[http://dx.doi.org/10.1016/j.biocel.2013.08.018] [PMID: 24004831]
[25]
Ghouri A, Conaghan PG. Update on novel pharmacological therapies for osteoarthritis. Ther Adv Musculoskelet Dis 2019; 11: 1759720X1986449.
[http://dx.doi.org/10.1177/1759720X19864492] [PMID: 31384314]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy